tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Hemab Therapeutics Holdings Ord Shs (Proposed)

COAG
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
40.860USD
+1.480+3.76%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
1.91B์‹œ๊ฐ€์ด์•ก
0.00P/E TTM

Hemab Therapeutics Holdings Ord Shs (Proposed) ์ •๋ณด ํšŒ์‚ฌ

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Hemab Therapeutics Holdings Ord Shs (Proposed) ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ COAG
ํšŒ์‚ฌ ์ด๋ฆ„Hemab Therapeutics Holdings Inc
์ƒ์žฅ์ผMay 01, 2026
CEOSorensen (Benny)
์ง์› ์ˆ˜- -
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ101 Main Street, Suite 1220
๋„์‹œCAMBRIDGE
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ02142
์ „ํ™”18004831140
์›น์‚ฌ์ดํŠธhttps://ir.hemab.com
์ข…๋ชฉ ์ฝ”๋“œ COAG
์ƒ์žฅ์ผMay 01, 2026
CEOSorensen (Benny)

Hemab Therapeutics Holdings Ord Shs (Proposed)์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Benny Sorensen, M.D., Ph.D.
Dr. Benny Sorensen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mads Behrndt-Eriksen
Mr. Mads Behrndt-Eriksen
Chief Financial Officer, General Manager
Chief Financial Officer, General Manager
--
--
Dr. Catherine Madigan, M.D.
Dr. Catherine Madigan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Ananthram Murthy, Ph.D.
Dr. Ananthram Murthy, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Chairman of the Board of Director
Chairman of the Board of Director
--
--
Ms. Linda Bain
Ms. Linda Bain
Director
Director
--
--
Dr. Laura Tadvalkar, Ph.D.
Dr. Laura Tadvalkar, Ph.D.
Director
Director
--
--
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Director
Director
--
--
Ms. Keli Walbert
Ms. Keli Walbert
Director
Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Benny Sorensen, M.D., Ph.D.
Dr. Benny Sorensen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mads Behrndt-Eriksen
Mr. Mads Behrndt-Eriksen
Chief Financial Officer, General Manager
Chief Financial Officer, General Manager
--
--
Dr. Catherine Madigan, M.D.
Dr. Catherine Madigan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Ananthram Murthy, Ph.D.
Dr. Ananthram Murthy, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Chairman of the Board of Director
Chairman of the Board of Director
--
--
Ms. Linda Bain
Ms. Linda Bain
Director
Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Hemab Therapeutics Holdings Ord Shs (Proposed)์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Hemab Therapeutics Holdings Ord Shs (Proposed)์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Benny Sorensen, M.D., Ph.D.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ